The most recent version of the European Society for Medical Oncology (ESMO) Clinical Practice Guidelines for the diagnosis, treatment and follow-up of metastatic non-small-cell lung cancer (NSCLC) was published in 2016. At the ESMO Asia Meeting in November 2017 it was decided by both ESMO and the Chinese Society of Clinical Oncology (CSCO) to convene a special guidelines meeting immediately after the Chinese Thoracic Oncology Group Annual Meeting 2018, in Guangzhou, China. The aim was to adapt the ESMO 2016 guidelines to take into account the ethnic differences associated with the treatment of metastatic NSCLC cancer in Asian patients. These guidelines represent the consensus opinions reached by experts in the treatment of patients with metastatic NSCLC representing the oncological societies of China (CSCO), Japan (JSMO), Korea (KSMO), Malaysia (MOS), Singapore (SSO) and Taiwan (TOS). The voting was based on scientific evidence, and was independent of both the current treatment practices and the drug availability and reimbursement situations in the six participating Asian countries. During the review process, the updated ESMO 2018 Clinical Practice Guidelines for metastatic NSCLC were released and were also considered, during the final stages of the development of the Pan-Asian adapted Clinical Practice Guidelines.

† Deceased. We dedicate this paper to Giorgio's memory. We will strive to make this experiment a great success and a tribute to his memory. He will be sorely missed. AbstractThe MoEDAL experiment at Point 8 of the LHC ring is the seventh and newest LHC experiment. It is dedicated to the search for highly ionizing particle avatars of physics beyond the Standard Model, extending significantly the discovery horizon of the LHC. A MoEDAL discovery would have revolutionary implications for our fundamental understanding of the Microcosm. MoEDAL is an unconventional and largely passive LHC detector comprised of the largest array of Nuclear Track Detector stacks ever deployed at an accelerator, surrounding the intersection region at Point 8 on the LHC ring. Another novel feature is the use of paramagnetic trapping volumes to capture both electrically and magnetically charged highly-ionizing particles predicted in new physics scenarios. It includes an array of TimePix pixel devices for monitoring highly-ionizing particle backgrounds. The main passive elements of the MoEDAL detector do not require a trigger system, electronic readout, or online computerized data acquisition. The aim of this paper is to give an overview of the MoEDAL physics reach, which is largely complementary to the programs of the large multi-purpose LHC detectors ATLAS and CMS. project grant; the V-P Research Notes 1 Defined to be a convolution of the efficiency and acceptance 2 The concept of Dirac (magnetic) charge is presented in Section 5. 3 If |n| = 1, this is only true for magnetic charge coupled to 2 H(S = 1, |q| = 1/2), 8 Li(S = 2, |q| = 3/2) and 10 B(S = 3, |q| = 5/2). 4 The reader should notice that the two-loop processes of Fig. 28(b), which couple the IC gluons to the fermionic SM sector suffer, in addition to the loop suppression, an additional helicity suppression, as compared to the diagram of Fig, 28(a), and are therefore non-leading contributions.

To assess the applicability of the National Institutes of Health (NIH) consensus criteria (NCC) for chronic graft-versus-host disease (cGVHD), 211 patients who developed GVHD more than 100 days after allogeneic transplantation were reclassified using NCC. Classifications were: late acute GVHD (44 patients, 21%), overlap syndrome (64 patients, 30%) and classic cGVHD (103 patients, 49%). Classic cGVHD and overlap syndrome patients (n ¼ 167) were graded using both the revised Seattle criteria (RSC) and NIH global scoring (NGS). Twenty-three patients (14%) had mild, 81 (48%) had moderate and 63 (38%) had severe cGVHD. After a median follow-up of 46 months (range 5-71 months), the 4-year GVHD-specific survival was not significantly different among the different subtypes of NCC. Among patients with late acute GVHD, however, the pattern of acute GVHD onset (late, persistent or recurrent) was significantly different with respect to GVHD-specific survival. Among patients with overlap syndrome and classic cGVHD, multivariate analysis showed that NGS as well as RSC were useful in predicting survival and discontinuation of immunosuppressive therapy despite of more detailed grouping. Our study indicates that NCC is applicable. The clinical impact of NIH types and NGS should be verified through prospective studies.

Our study shows that the investigation of vascular patterns by using dermoscopy can be valuable for the clinical diagnosis and differentiation of scalp psoriasis and seborrhoeic dermatitis.

We conducted a systemic evaluation to describe the effect of minimal residual disease (MRD) kinetics on long-term allogeneic transplantation outcome by analyzing 95 adult transplants with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph-positive ALL) who received first-line two courses of imatinib-based chemotherapy (median follow-up 5 years). MRD monitoring was centrally evaluated by real-time quantitative PCR (4.5 log sensitivity). After the first course of imatinib-based chemotherapy, 33 patients (34.7%) achieved at least major molecular response. On the basis of MRD kinetics by the end of two courses of imatinibbased chemotherapy, we stratified entire patients into four subgroups: early-stable molecular responders (EMRs, n ¼ 33), late molecular responders (LMRs, n ¼ 35), intermediate molecular responders (IMRs, n ¼ 9) and poor molecular responders (PMRs, n ¼ 18). Multivariate analysis showed that the most powerful factor affecting long-term transplantation outcome was MRD kinetics. Compared with EMRs, IMRs or PMRs had significantly higher risk of treatment failure in terms of relapse and disease-free survival (DFS). LMRs had a tendency toward a lower DFS. Quantitative monitoring of MRD kinetics during the first-line imatinib-based chemotherapy course is useful in identifying subgroups of Ph-positive ALL transplants at a high risk of relapse.